ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 140 for:    regorafenib

Study of Regorafenib and Sildenafil for Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02466802
Recruitment Status : Recruiting
First Posted : June 9, 2015
Last Update Posted : January 26, 2018
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Virginia Commonwealth University

Brief Summary:
This is a phase 1 study of sildenafil in combination with regorafenib in patients with progressive advanced solid tumors. A modified 3+3 dose escalation design will be conducted for the dose escalation of the treatment combination: additional patients will be enrolled at the MTD until a total of 12 patients have been treated at the MTD.

Condition or disease Intervention/treatment Phase
Solid Tumor Drug: Regorafenib Drug: Sildenafil Citrate Phase 1

Detailed Description:

This study is a single-arm, open-label, phase 1 trial to determine the RP2D of the combination of regorafenib and sildenafil. Both study medications will be taken orally on days 1-21 of each 28-day cycle.

Using a modified 3+3 dose escalation design, 3-6 patients with an advanced solid tumor will be enrolled at each dose level. Additional patients will be enrolled at the MTD until a total of 12 patients have been treated at the MTD.

Eligible patients will have received available standard treatments. Patients with solid tumors for which regorafenib would be considered a standard treatment are eligible as long as regorafenib has not been previously administered.

Blood samples will be collected for correlative studies including PK, PD, and CTCs. Tumor samples archived from a previous biopsy or surgery will also be collected for correlative studies.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 37 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of Regorafenib and Sildenafil for Advanced Solid Tumors
Actual Study Start Date : July 1, 2015
Estimated Primary Completion Date : August 31, 2018
Estimated Study Completion Date : June 30, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: A: regorafenib and sildenafil citrate
Patients receive regorafenib and sildenafil citrate by mouth every day (PO QD) on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: Regorafenib
Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors. Regorafenib Administration and Treatment Schedule. Regorafenib will be taken orally once daily for the first 21 days of each 28-day cycle. Regorafenib will not be taken on the last 7 days of each cycle. Patients will be instructed as follows: Take regorafenib once daily with a low fat meal that contains less than 30% fat. Take the regorafenib tablets at about the same time each day. Swallow the tablets whole.
Other Names:
  • Stivarga
  • 755037-03-7
  • BAY 73-4506

Drug: Sildenafil Citrate
Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors.Sildenafil Administration and Treatment Schedule. Sildenafil will be taken orally once daily at the same time the regorafenib dose is taken for the first 21 days of each 28-day cycle. Sildenafil will not be taken on the last 7 days of each cycle.
Other Names:
  • Viagra
  • SILDENAFIL
  • Revatio
  • 171599-83-0




Primary Outcome Measures :
  1. To determine the recommended phase 2 dose (RP2D) of the combination of regorafenib and of sildenafil when given to patients with advanced solid tumors. [ Time Frame: 28 days ]
    Patients' treatment dosing level, dose modification, DLTs, and evaluability for DLTs will be listed and summarized by basic descriptive statistics (such as frequency and proportion). The MTD/RP2D will be found based on the Definitions of Dose-Limiting Toxicity, Maximum Tolerated Dose, and Recommended Phase 2 Dose. RP2D for the combination of regorafenib and sildenafil that is less than or the same as the MTD.


Secondary Outcome Measures :
  1. To evaluate the safety and toxicity of the regorafenib and sildenafil combination [ Time Frame: Up to 30 days after completion of study treatment ]
    Adverse events reported according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0. Adverse events (AEs) characterized and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI CTCAE v4.0) to determine safety and toxicity of the combination of regorafenib and sildenafil.

  2. To explore the antitumor effects of the regorafenib and sildenafil combination [ Time Frame: Up to 30 days after completion of study treatment ]
    Tumor response based on Response Evaluation Criteria in Solid Tumors (RECIST version 1.1)

  3. To determine the pre-treatment expression of phosphodiesterase type 5 (PDE5) in tumor samples [ Time Frame: 12- 24 months ]
    Pre-treatment PDE5 expression identified by immunohistochemistry using archived tumor tissue. Pre-treatment PDE5 expression identified by immunohistochemistry (IHC) using archived tumor tissue.

  4. To evaluate the impact of sildenafil on the pharmacokinetics of regorafenib [ Time Frame: 12-24 months ]
    Regorafenib plasma concentration measured at a total of 6 time points: at baseline (pre-treatment) and at 5 time points in cycle 1. Plasma concentration of regorafenib measured at 6 time points: at baseline (pre-treatment) and in cycle 1 on day 1 (post-treatment), on day 15 (pre- and post-treatment), and on day 21 (pre- and post-treatment)


Other Outcome Measures:
  1. To explore the PD relationships between regorafenib and tumor response [ Time Frame: 12-24 months ]
    Quantity of total and free regorafenib measured by in vitro RAF-1 kinase activity inhibition using plasma samples collected at baseline (pre-treatment) and in cycle 1 (post-treatment on day 1, pre- and post-treatment on day 15, and pre- and post-treatment on day 21)

  2. To assess the feasibility of isolating, enumerating, and analyzing CTCs to characterize cGMP within tumor cells [ Time Frame: Up to 30 days after completion of study treatment ]
    Characteristics of cGMP found in CTCs isolated and enumerated using the ApoStream DEPfff enrichment device with blood samples collected at baseline (pre-treatment), on days 1 and 15 in cycle 1, and at the time of each tumor response assessment

  3. To assess the bioactivity of sildenafil in plasma [ Time Frame: 12-24 months ]
    Quantity of total sildenafil measured by elevated VASP-1 phosphorylation ex vivo using plasma samples collected at baseline (pre-treatment) and in cycle 1 (post-treatment on day 1, pre- and post-treatment on day 15, and pre- and post-treatment on day 21)

  4. To assess the cytokine/growth factor levels in plasma [ Time Frame: Up to day 21 of course 1 ]
    Quantity of cytokines/growth factors measured using a Bio-Rad MAGPIX multiplex reader ex vivo using plasma samples collected at baseline (pre-treatment) and in cycle 1 (post-treatment on day 1, pre- and post-treatment on day 15, and pre- and post-treatment on day 21)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

• Advanced solid tumor that has progressed during or after treatment with approved therapies or for which there is no standard effective therapy available

  • Note: patients with solid tumors for which regorafenib would be considered a standard treatment are eligible as long as regorafenib has not been previously administered

    • Measurable or evaluable disease by RECIST v1.1
    • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
    • Absolute neutrophil count (ANC) >= 1500/mm^3
    • Platelets >= 100,000/mm^3
    • Hemoglobin > 9 g/dL (untransfused)
    • Creatinine =< 1.5 x upper limit of normal (ULN) for the laboratory or calculated or actual creatinine clearance >= 60 mL/min
    • Proteinuria =< grade 1 (ie, =< 1+ [30 mg/dL] using a random urine sample or < 1.0 gm using a 24-hour sample)
  • Note: if urine sample indicates >= grade 2 proteinuria (ie, 2+ [100 mg/dL]), a 24-hour urine sample must be collected and tested; urine protein in the 24-hour sample must be < 1.0 gm/24 hours • Total bilirubin =< 1.5 x ULN for the laboratory
  • Exception: if a patient has documented Gilbert's syndrome and a total bilirubin is > 1.5 x ULN, the total bilirubin requirement may be waived provided the direct bilirubin is within normal limits (WNL) for the laboratory

    • Aspartate aminotransferase (AST) =< 2.5 x ULN for the laboratory
    • Alanine aminotransferase (ALT) =< 2.5 x ULN for the laboratory
    • Alkaline phosphatase =< 2.5 x ULN for the laboratory (=< 5 x ULN for patients with cancer involving the liver and/or bone)
    • Non-hematologic toxicities from previous cancer therapies resolved to =< grade 1
    • International normalized ratio (INR) is =< 1.5
    • Activated partial thromboplastin time (aPTT) =< 1.5 x ULN for the laboratory
    • Left ventricular ejection fraction (LVEF) assessed by echocardiogram within 3 months prior to initiation of study treatment indicates an LVEF of >= 50%
    • A woman of childbearing potential (WCBP), defined as a woman who is < 60 years of age and has not had a hysterectomy, must have a documented negative serum pregnancy test within 7 days prior to initiating study treatment
    • A WCBP and a male patient with a partner who is a WCBP must agree to use a medically accepted method for preventing pregnancy for the duration of study treatment and for 2 months following completion of study treatment
    • Ability to understand and willingness to sign the consent form written in English
  • Note: the consent form must be signed prior to the conduct of any trial-specific procedure

Exclusion Criteria:

  • Meningeal metastases or brain metastases that are symptomatic or untreated * Note: patients who are asymptomatic and have had post-treatment imaging that indicates stable brain disease are eligible; (patients with meningeal metastasis are not eligible even if stable following treatment); also, note that brain imaging is required within 8 weeks prior to initiation of study therapy
  • Any investigational agent within 4 weeks prior to initiating study treatment
  • Previous therapy with regorafenib
  • If sorafenib was previously administered, intolerance to sorafenib
  • Inability to swallow medication
  • Known or suspected malabsorption condition or obstruction
  • Contraindications to sildenafil including:

    • Known retinitis pigmentosa
    • History of priapism related to PDE5 inhibitors (eg, sildenafil, vardenafil, tadalafil)
    • Presence of nonmalignant hematologic disorders, such as sickle cell disease, that may increase the risk of priapism
  • Contraindication to antiangiogenic agents, including:

    • Serious non-healing wound, non-healing ulcer, or bone fracture
    • Major surgical procedure or significant traumatic injury within 4 weeks prior to initiating study treatment
    • Pulmonary hemorrhage/bleeding event >= grade 2 within 12 weeks prior to initiating study treatment
    • Any other hemorrhage/bleeding event >= grade 3 within 12 weeks prior to initiating study treatment
  • History of organ allograft including corneal transplant
  • Any documented history of thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident, transient ischemic attack, deep vein thrombosis, or pulmonary embolism within 6 months prior to initiating study treatment

    * Note: patients with a tumor-associated thrombus of locally-involved vessels should not be excluded from participating in the study

  • Evidence of bleeding diathesis or coagulopathy
  • Resting systolic blood pressure (BP) < 100 mmHg
  • Hypertension defined as systolic BP >= 140 mmHg or diastolic BP >= 90 mmHg despite optimal medical management
  • Active or clinically significant cardiac disease including any of the following:

    • Unstable angina (eg, anginal symptoms at rest) or onset of angina within 3 months prior to initiating study treatment
    • Myocardial infarction within 6 months prior to initiating study treatment
    • Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers
    • New York Heart Association (NYHA) class III or IV congestive heart failure
  • Seizure disorder requiring medication
  • Serious (ie, >= grade 3) uncontrolled infection
  • Known human immunodeficiency virus (HIV) seropositivity

    * Note: HIV testing is not required

  • Chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
  • Pleural effusion or ascites that causes respiratory compromise (ie, >= grade 2 dyspnea)
  • Untreated or metastatic pheochromocytoma
  • Planned ongoing treatment with other drugs thought to potentially have adverse interactions with either of the medications included in the study treatment, for example:

    • Alpha 1-blockers
    • Vasodilators, such as nitrates
    • Other PDE5 inhibitors, eg, vardenafil, tadalafil
    • Therapeutic anticoagulation with vitamin K antagonists (eg, warfarin), heparins and heparinoids, or direct thrombin inhibitors (DTIs) ** Note: prophylactic low-dose anticoagulation to maintain vascular access devices or low-dose daily aspirin for cardiac health is permitted
    • Immunosuppressants such as tacrolimus, leflunomide or tofacitinib, roflumilast, pimecrolimus

      ** Note: administration of steroids as part of symptom management or for other supportive care purposes is permitted

    • STRONG cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitors and/or STRONG CYP3A4 inducers ** Note: if such medications have been used, patients must have discontinued these agents >= 2 weeks prior to initiating study treatment
  • Pregnancy or breastfeeding
  • Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02466802


Contacts
Contact: Karly Rogers, RN 804-628-0960 masseysiit@vcu.edu
Contact: Andrew S. Poklepovic, MD 804-628-2321 andrew.poklepovic@vcuhealth.org

Locations
United States, Virginia
Virginia Commonwealth University/Massey Cancer Center Recruiting
Richmond, Virginia, United States, 23298
Contact: Andrew Poklepovic, MD    804-628-2321    apoklepovic@mcvh-vcu.edu   
Contact: Karly Rogers, RN    804-628-0960    masseysiit@vcu.edu   
Principal Investigator: Andrew Poklepovic, MD         
Sponsors and Collaborators
Virginia Commonwealth University
Bayer
Investigators
Principal Investigator: Andrew S. Poklepovic, MD Massey Cancer Center

Responsible Party: Virginia Commonwealth University
ClinicalTrials.gov Identifier: NCT02466802     History of Changes
Other Study ID Numbers: MCC-13-09812
HM20004297 ( Other Identifier: IRB )
NCI-2015-01101 ( Registry Identifier: NCI )
First Posted: June 9, 2015    Key Record Dates
Last Update Posted: January 26, 2018
Last Verified: January 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by Virginia Commonwealth University:
Advanced

Additional relevant MeSH terms:
Citric Acid
Sildenafil Citrate
Anticoagulants
Calcium Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Urological Agents